Mutations in the infamous BRCA gene are synonymous with breast cancer and women who carry a BRCA mutation also have a high risk of developing gynecologic cancers. A recent Phase II study, presented at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer (FL, USA), has shown that gynecologic cancer cells that have a BRCA mutation appear to be sensitive to veliparib. This drug works by targeting an enzyme called PARP, which is essential in enabling cancer cells to repair themselves after DNA damage. As such, veliparib has been effective when combined with chemotherapy but it has not been identified if the drug is effective when used as a single agent, until this recent trial.
Robert Coleman, lead author of the study and Professor and Vice Chair of Clinical Research at the University of Texas MD Anderson Cancer Center (TX, USA), explained that "One criticism of the PARP drugs is they are not active in patients who have developed resistance to other therapies, but we found veliparib appears to be effective in some platinum-resistant patients with recurrent or persistent disease." Coleman continued "Most of these patients have run out of treatment options, and it is very hopeful to potentially have another therapy to offer them."
A twice-daily dose of veliparib was given to 50 patients with BRCA gene mutations. Disease was stabilized for more than 4 months in over half of the patients (26) and overall 26% of patients responded positively to the treatment, with their tumors reducing in size. In addition, tumors in two patients completely disappeared.
Coleman concluded "Patient recruitment can be a problem for many clinical trials, however, this one filled up very quickly, which reflects that women and their doctors understand that PARP inhibitors hold real promise." 
News
According to their study, published in Nature Genetics in March 2014, an international research team has identified a mutation in SMARCA4 as the cause of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
In general, ovarian is the fifth leading cause of cancer death in American women. SCCOHT is an extremely rare form of ovarian cancer that mostly strikes young women and girls. Moreover, it is extremely aggressive, owing to the frequent late stage at which the cancer is diagnosed and its lack of responsiveness to chemotherapy, which results in 65% of patients not surviving beyond 2 years.
The Translational Genomics Research Institute (TGen, AZ, USA) led and coordinated several institutes, including Mayo Clinic, Johns Hopkins University, St Joseph's Hospital and Medical Center, Evergreen Hematology and Oncology, Children's Hospital of Alabama, the Autonomous University of Barcelona, British Columbia Cancer Agency, University of British Columbia and the University Health Network-Toronto, in order to study the genetics of SCCOHT via whole-exome sequencing.
"We set out to uncover any small sliver of hope for women afflicted with this rare cancer. What we found instead are the nearly universal underpinnings of SCCOHT," explained Pilar Ramos, a TGen Research Associate and lead author of the study. "By definitively identifying the relationship between SMARCA4 and SCCOHT, we have high confidence that we have set the stage for clinical trials that could provide patients with immediate benefit."
Their analysis identified both germline and somatic inactivating mutations in the chromatin-remodeling gene SMARCA4 in nine out of 12 SCCOHT cases (75%) and SMARCA4 protein loss in 14 out of 17 SCCOHT tumors (82%), but only two out of 485 other primary ovarian tumors (0.4%), strongly suggesting the mutation causes SCCOHT as loss of the protein was specific to SCCOHT cases. As well as being the only recurrently mutated gene identified in the study, the results have been further validated by two other new studies recently reporting similar results, reflecting a scientific consensus that usually takes months or even years to accomplish.
By identifying a genetic factor the team have paved the way for development of a genetic test, which could help diagnose the disease earlier and therefore save lives, as well as develop new methods of treatment. As SMARCA4 has previously been associated with other cancers, any targeted treatments developed against this gene or protein could have therapeutic efficacy against these cancers too.
Much of the work in this study was inspired by the memory of Taryn Ritchey, a 22-year-old TGen patient who lost her fight with ovarian cancer in 2007. "Taryn would be incredibly excited about this amazing new study, and she would be glad and thankful that other young women like her might now be helped because of TGen's ongoing research," comments Taryn's mother Judy Jost. (5), 427-429 (2014) ; TGen press release: www.tgen.org/ news/2014-media-releases/tgen-study-discovers-genetic-cause-of-rare-type-of-ovarian-cancer.aspx#.UzCaA_l_vwh "By definitively identifying the relationship between SMARCA4 and SCCOHT, we have high confidence that we have set the stage for clinical trials that could provide patients with immediate benefit. " future science group
The researchers found that the cells of women with BRCA1 mutations cannot effectively fight the particularly high levels of estrogen present in the breasts and ovaries of all women. This in turn leaves these cells vulnerable to dangerous DNA damage and resulting cancer development. This link between estrogen levels and the BRCA1 mutation and resulting breast/ovarian cancers has been suspected for some years but was unproven until this new research was carried out. Currently, around one in 1000 women in the UK carries the BRCA1 mutation, which was recently brought to international media attention when actress Angelina Jolie underwent a double mastectomy as a result of having this genetic condition. Women with this condition have up to an 85% increased risk of developing breast cancer and up to a 40% increased risk of developing ovarian cancer.
Prior to this research, the only treatment option available to reduce the risk of developing both cancer types has been irreversible preventive surgery -a mastectomy (breasts) and an oophorectomy (ovaries). However, the new discovery from the Queen's researchers could mean that women affected with BRCA1 mutations could instead use already available drugs.
Lead author of this study Kienan Savage explained, "This discovery is very significant in the management of women with the BRCA1 gene mutation. It's the first really credible evidence that estrogen is driving cancer in women with a BRCA1 gene mutation. Because of this discovery, we now have the opportunity to propose an alternative treatment to surgery. It also opens up the possibility of pausing treatment for a period in order for women to have children, if desired … What also makes this exciting is that there are drugs already on the market which turn off estrogen production. In theory, we could use these drugs to chemically reduce estrogen production in women, which could negate the need for irreversible surgery."
The researchers from Queen's Centre for Cancer Research and Cell Biology are now seeking funding to launch clinical trials and hope to do so within 12 months. The team demonstrated that woman who reported use of hormone therapy during menopause were 30% less likely to develop B-cell non-Hodgkin lymphoma, compared with those who had not received such thera-pies. Furthermore, women who initiated menopausal hormone therapy at 45 years of age or less were associated with a further decrease in risk, being approximately 40% less likely to be diagnosed with B-cell non-Hodgkin lymphoma.
"The connection between lymphomas and menopausal hormone therapy use hinges on understanding the disease's biology and the window of susceptibility," Wang commented. "Hormone therapy is of interest because the loss of estrogen coupled with aging in women result in decreased immune function, which can elevate risk of non-Hodgkin lymphoma."
While stating that the results support part of her hypothesis, Wang indicates that further work is required in order to establish the exact mechanisms that may be behind this apparent decrease in B-cell non-Hodgkin lymphoma risk. It is proposed that the reduction in risk may be the result of such hormone therapies supporting maintenance of a healthy immune system or reducing inflammation.
Based on well-established evidence linking menopausal hormone therapy with other cancer types, women using such therapies are advised to at the lowest effective future science group News dose for the shortest amount of time needed. Wang cautioned that the findings of this study are preliminary and should not change current recommendations and guidelines for menopausal hormone therapy use.
-Written by Emily Brown
Source: City of Hope press release: http://breakthroughs. cityofhope.org/aacr-2014-hormone-therapy-non-hodgkin-lymphoma Researchers from the Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center (NH, USA) used data collected by the Ovarian Cancer Association Consortium to identify 'uncommon' genetic risk variants in unexplored regions of the genome.
"Ovarian cancer is the leading cause of death from gynecologic malignancy, and it is typically diagnosed at an advanced stage with little chance for cure," said Jennifer Doherty, a member of the Dartmouth-Hitchcock Norris Cotton Cancer Center and a coauthor of the study.
Jenny Permuth Wey, an applied research scientist in the Department of Cancer Epidemiology at Moffitt Cancer Center and coinvestigator explained "We are trying to identify new 'spelling mistakes,' or variants in the genetic code, that may influence a woman's risk for ovarian cancer." Permuth Wey explained "We are particularly interested in genetic variants that are not common in the population (those carried by less than one and 20 women) because uncommon variants are not well studied and evidence suggests they may significantly contribute to cancer risk." "This collaborative effort including 19 studies from the international Ovarian Cancer Association Consortium provides clues that will lead to a better understanding of how and why ovarian cancer develops, and may also inform targeted treatment, prevention and screening strategies" concluded Doherty. . 23(4), 584-593 (2014) . In a recent study, conducted using data from a cohort of 12,193 women who took clomiphene citrate or gonadotrophins as part of fertility treatment evaluated for infertility between 1965 and 1988 at five sites in the USA, no increased risk of breast cancer over 30 years of follow-up was observed. During the 30 years of follow-up, 749 cases of breast cancer were observed. Overall, use of clomiphene citrate was not associated with risk of breast cancer. However, an elevated risk for invasive breast cancer was observed in some patients who received 12 or more cycles of clomiphene. Women who remained nulligravid after taking gonadotrophins and clomiphene citrate also appeared to have an increased risk of invasive cancers. This risk is likely owing to an effect of the underlying cause of infertility but these results do highlight the importance of continued monitoring of these patients. JAMA 311(10), 1023-1034 (2014) . Scientists in a NIH research network have found that two surgical treatments for pelvic organ prolapse have similar rates of success and safety. Sacrospinous ligament fixation and uterosacral ligament suspension are common procedures performed to correct apical prolapse. Many women also receive behavioral therapy with pelvic floor muscle training and it is unknown whether this is associated with improved outcomes. A total of 374 women with vaginal prolapse and urinary incontinence were included in the study, with 188 randomly assigned to undergo uterosacral ligament suspension and 186 randomized to receive sacrospious ligament fixation. Of these patients, 186 women were randomized to a guided exercise course to strengthen the pelvic muscles. After 2 years, neither surgical procedure was significantly superior to the other after factoring in anatomical, functional or adverse event outcomes. The perioperative guided exercise program was not significantly associated with any additional benefit to most participants.
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